Abstract
We studied the efficacy and safety of the recombinant HB vaccine prepared from Chinese hamster ovary cells in 52 healthy volunteers who were negative for HBsAg and HBsAb, 10 males and 42 females, the mean (±SD) age was 35.2±9.4 years old (range, 18 to 57). They were grouped by subcutaneous and intramuscular injections and received three doses of the vaccine (10μg each), at 0.1 and 6 months. HBs antibody was induced in 48 (92%) out of 52 subjects at the 4th week after the third vaccination. There was no significant difference in positive rate of HBs antibody between subcutaneous and intramuscular groups. Slight adverse effects were seen in 30 occasions (15.4%) out of 159 injections.
Thus, immunization of this HB vaccine appeared to be useful and safe, if compared wtih the plasma-derived HB vaccine.
